Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States
Between 2009 and 2021, there was increasing use of EBRT and SBRT, whereas use of RP remained stable. Although BT was the least costly, its utilization as monotherapy and combined with EBRT declined.
Authors
- Shreyas Joshi (ORCID: https://orcid.org/0000-0002-0020-5298)
- Pretesh Patel (ORCID: https://orcid.org/0000-0002-3522-1204)
- Bruce Hershatter
- Vishal R. Dhere (ORCID: https://orcid.org/0000-0002-8364-7488)
- Sagar A. Patel (ORCID: https://orcid.org/0000-0001-5174-2096)
- Dattatraya Patil (ORCID: https://orcid.org/0000-0002-8242-9825)
- Adam Lorentz (ORCID: https://orcid.org/0000-0002-8943-9049)
- Aaron D. Weiss
- Karen D. Godette
- Martin G. Sanda (ORCID: https://orcid.org/0000-0003-4288-5786)
- Nikhil Sebastian (ORCID: https://orcid.org/0000-0002-3977-7867)
- Ashesh B. Jani
Institutions
- Emory University (US)
- Piedmont Cancer Institute (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1002/cncr.35795
- Citations
- 3
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56